UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~December~~January 179, ~~2019~~2020

FOAMIX PHARMACEUTICALS LTD.

(Exact name of registrant as specified in its charter)

Israel	001-36621	N/A
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2 Holzman Street,

Weizmann Science Park

Rehovot, Israel

7670402

(Address of principal executive offices)

(Zip Code)

+972-8-9316233

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Ticker symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value NIS 0.16 per share		FOMX		Nasdaq Global Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x¨

Item 28.0301 ~~Creation~~Other ~~of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant~~Events.

On ~~December~~January 179, ~~2019~~2020, ~~Foamix Pharmaceuticals~~ ~~Inc. (the “Borrower”), a direct wholly owned subsidiary of~~ Foamix Pharmaceuticals Ltd. ~~(the~~issued ~~“Company”), drew~~a ~~down~~press ~~the~~release ~~second~~announcing ~~tranche~~that ofits ~~$20.0~~novel ~~million~~AMZEEQ™ (~~the “Tranche 2 Loan”~~minocycline) ~~under the previously disclosed Credit Agreement~~topical ~~and Guaranty (the “Credit Agreement”)~~foam, ~~dated~~4% aswill ofbe ~~July~~available ~~29,~~on ~~2019,~~January ~~among the Company~~13, ~~the~~2020 ~~Borrower,~~by ~~the~~prescription ~~subsidiary~~for ~~guarantors from time to time party thereto,~~ the ~~lenders~~treatment ~~from~~of ~~time~~inflammatory tolesions ~~time~~of ~~party thereto and Perceptive Credit Holdings II, LP, as Administrative~~non-nodular ~~Agent.~~moderate ~~As previously disclosed, the Credit Agreement provides for up~~ to asevere ~~$50.0~~acne ~~million~~vulgaris ~~term~~in ~~loan~~adults ~~facility, $15.0 million of which was borrowed at closing on July 29, 2019 (the “Tranche 1 Loan”). The Tranche 1 Loan~~ and ~~the~~pediatric ~~Tranche~~patients 29 ~~Loan~~years ~~each have a maturity date~~ of ~~July~~age ~~29,~~and ~~2024, unless earlier prepaid~~older. ~~Pursuant~~A tocopy ~~the~~of ~~Credit Agreement and subject to~~ the ~~achievement~~press ofrelease ~~certain~~is ~~revenue~~attached ~~milestones~~as ~~prior~~Exhibit to99.1 ~~September 30, 2020, the Borrower would have the right~~ to ~~draw~~this ~~down a third tranche of up to $15~~report.~~0 million.~~

~~The~~Item ~~Company~~9.01 ~~expects~~Financial toStatements ~~use the proceeds of the Tranche 2 Loan for the commercial launch of AMZEEQ™, certain pipeline development activities~~ and ~~other general corporate purposes~~Exhibits.

~~The~~(d) description of the Credit Agreement included in Item 1.01 of the Company’s Current Report on Form 8-K filed on July 30, 2019 is incorporated herein by reference. The description of the Credit Agreement contained herein does not purport to be complete, and is qualified in its entirety by reference to the complete text of the Credit Agreement filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, filed on November 12, 2019.Exhibits

SIGNATURES

Exhibit No.		Description

99.1		Press release entitled “Foamix Announces AMZEEQ^™ (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne,” dated January 9, 2020.

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~SIGNATURES

~~Date:~~Pursuant ~~December~~to 18the requirements of the Securities Exchange Act of 1934, ~~2019~~the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~FOAMIX PHARMACEUTICALS LTD. By~~Date: ~~/s/~~January ~~Mutya~~9, ~~Harsch Mutya Harsch Chief Legal Officer~~2020

	FOAMIX PHARMACEUTICALS LTD.

	By:	/s/ Mutya Harsch
		Mutya Harsch
		Chief Legal Officer

Filing Compare · Foamix Pharmaceuticals Ltd.